Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors.
With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.
With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.
Location: Canada
Employees: 11-50
Total raised: $95M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.10.2025 | Series D | $35M | J.P. Morga... |
| 08.12.2022 | Series C | $30M | - |
| 08.04.2019 | Series B | $30M | - |
Mentions in press and media 10
| Date | Title | Description |
| 16.10.2025 | ABK Biomedical Secures $35M: Advancing Imageable Embolotherapy for Cancer | ABK Biomedical secured $35M Series D funding, led by J.P. Morgan Life Sciences. This investment fuels Eye90 microspheres' clinical operations, commercialization, and manufacturing expansion. Eye90, an FDA Breakthrough Device, enhances Y90 r... |
| 15.10.2025 | ABK Biomedical: $35 Million Series D Secured For Advancing Clinical Development Of Eye90 Microspheres | ABK Biomedical, a medical device company specializing in advanced imageable embolic technologies, has raised an oversubscribed $35 million in its Series D funding round. The investment was led by new investor J.P. Morgan Life Sciences Priva... |
| 14.10.2025 | ABK Biomedical Raises US$35M in Series D Funding | ABK Biomedical, Inc., an Halifax, NS, Canada-based innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, raised US$35m in Series D financing. The round... |
| 08.12.2022 | Canada-based ABK Biomedical raises USD 30 million in oversubscribed Series C round | Canada-based innovative medical device company, ABK Biomedical, raised USD 30 million in recent financing. The oversubscribed Series C round took place on December 6, 2022. Santé Ventures, along with a significant, undisclosed MedTech strat... |
| 07.12.2022 | ABK Biomedical Raises USD30M in Series C Financing | ABK Biomedical, a Halifax, Canada-based medical device company, raised USD30M in Series C funding. The round was led by Santé Ventures with participation from F-Prime Capital and Eight Roads Ventures. The company intends to use the funds to... |
| 06.12.2022 | ABK Biomedical Raises USD 30M in Series C Financing | - |
| 08.04.2019 | ABK Biomedical Raises $30M in Series B Financing | - |
| 08.04.2019 | Daily funding roundup - April 8th, 2019 | Simudyne raised $6M; Jebbit landed $12M; VSCO secured $15M; RiskLens received $20.6M Budbee: Budbee is a Stockholm-based IT startup tired of bad home deliveries - a last mile delivery experience suited for your needs. Budbee has raised €4.8... |
| 08.04.2019 | ABK Biomedical Raises $30M in Series B Funding | ABK Biomedical, Inc., a Halifax, Nova Scotia, Canada-based medical device company dedicated to the research, development and commercialization of innovative embolic therapies, raised $30m in Series B funding. The round was co-led by F-Prime... |
| - | ABK Biomedical | “At ABK biomedical, we are focused on developing novel Y90 radioembolization treatment options for patients with hypervascular liver tumors” |